TAGline 1995 – Treatment Action Group

Archives:

December 1995

CMV’s Real World: When Two Prophylaxis Studies Declare Opposite Findings, Clinicians And Their Patients Are Lost in the Quandary
Giving Away the Farm: How Corporate Cynicism, Savvy Schmoozing and Relentless PR Paved The Way to Unqualified Approval for Two New Antiretrovirals
Random Gleanings: Tracking Down the Elusive CD8 Cell Factor; FDA Panel Recommends Approval for Ganciclovir Implant; FDA Approval for Saquinavir; Lottery for Ritonavir

Antiretroviral Horizon: 35th Interscience Conference Unveils Results from Several Important Clinical Studies
I’ll Take Los Angeles: AIDS Treatment Activists from Across the Land Gather to Share Expertise and Ideas
Random Gleanings: FDA Antiviral Drugs Advisory Committee; Ambushed in the FDCs; Expanding T cells: Koenig weighs in on Good CTLs/Bad CTLs debate

Kiss My Access: Community Envoy to Food and Drug Panel Urges Caution in Approving New Anti-HIV Therapueutics and in Providing Early Access
Reversal of Fortune: Despite Pressure to Crown Combo King, 175 Investigators Soft-Pedal Combination Nucleoside Study’s Startling Findings
Washington Woes
Conclusions for ACTG 175

Batten Down the Hatches: House Republican Plan Calls for AIDS Research Dollars to Be Mixed Into Pot For All to Avail Themselves Of
Combo Jumbo: Controversial Nucleoside Study Awakens To A World Strangely Disaffected By Its Prepackaged Proclamation

Science South of the Border: Feel Good Merck Meeting Leaves Everybody Agreeing, But Brazil Study Bodes Ill for the Future
Diversity Threshold: New Model of Immune Defense to HIV Shows How Nature of Response Might Determine Eventual Outcome

Bottom of the Ninth: With Two Down And Integrase On Deck, AIDS Research Team Hopes For a Hit–Or Will It Be ‘Three Up, Three Down?’
Like Pulling Teeth: FDA’s Oncological Drug Advisory Committee Recommends DOX-SL for Accelerated Approval–But Not Without A Fight

Random Gleanings: FDA Just Says “No” To Salk Immunogen; Heralding the Naked Emperor, Part II; OAR’s Dr. Paul Speaks; Varmus Selects New Director for Office of Alternative Medicine
Battle Lost: Merck’s Scientists Cave In To The Vogue of Surrogate Marker Endpoint Trials, Accelerated Approval And Quick Cash
Dendritic Cells in Drag: Inauspicious Debut for HIV Specific CTLs; New Concerns about IL-12; Neutralizing Approaches for “Bad” Cytokines; Parke-Davis Targets Cellular Factors

Pulling the Plug on T-Cells: Fascinating Work on HIV and T-Cell Kinetics Challenges Longtime Dismissal of Ravaged Immune System’s Regenerative Potential
Re-Inventing Government: New ACTG Structure Squeezes Eleven Committees Into Three–But Will Anything Really Be Any Different?
Hope for Sale: Like the Wings of Icarus, Treatment Hype Sweeps Its prey Upward to the Heavens, Then Plucks Them Down Into icey Waters

The Cycles of History: With Good Intenntions, Over-Zealous Researchers May Be Setting the Stage For Yet Another Colossal Failure
Tyranny of the Minority: What the New Republican Congress Will Mean for AIDS Prevention, Treatment and Research